Patents by Inventor Soeren Padkjaer

Soeren Padkjaer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210253697
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 19, 2021
    Inventors: Vibeke Westphal STENNICKE, Christine Brender READ, Susanne Nedergaard GRELL, Charlotte WIBERG, Rune SALBO, Anette HENRIKSEN, Soeren PADKJAER
  • Patent number: 10906975
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: February 2, 2021
    Assignee: NOVO NORDISK A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Publication number: 20190194321
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: December 4, 2018
    Publication date: June 27, 2019
    Applicant: Novo Nordisk A/S
    Inventors: Vibeke Westphal STENNICKE, Christine Brender READ, Susanne Nedergaard GRELL, Charlotte WIBERG, Rune SALBO, Anette HENRIKSEN, Soeren PADKJAER
  • Patent number: 10189904
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: January 29, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Publication number: 20180105590
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: December 8, 2016
    Publication date: April 19, 2018
    Inventors: Vibeke Westphal STENNICKE, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune SaIbo, Anette Henriksen, Soeren Padkjaer
  • Patent number: 9908944
    Abstract: The present invention relates to a method of identifying urokinase plasminogen activator (uPA) antibodies. The invention also relates to antibodies that are capable of binding uPA and which are capable of reducing or inhibiting uPA activity. Furthermore, the invention relates to uses for such antibodies, such as therapeutic and pharmaceutical uses.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: March 6, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Padkjaer, Jesper Pass, Gustav Roeder, Kasper Almholt, Pernille A. Usher
  • Publication number: 20170305994
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 26, 2017
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Patent number: 9737612
    Abstract: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: August 22, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Albrecht Gruhler, Susanne Nedergaard Grell, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Patent number: 9713644
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: July 25, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Publication number: 20170190775
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: December 8, 2016
    Publication date: July 6, 2017
    Inventors: Vibeke Westphal STENNICKE, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune SaIbo, Anette Henriksen, Soeren Padkjaer
  • Patent number: 9550830
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: January 24, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Publication number: 20160159924
    Abstract: The present invention relates to a method of identifying urokinase plasminogen activator (uPA) antibodies. The invention also relates to antibodies that are capable of binding uPA and which are capable of reducing or inhibiting u PA activity. Furthermore, the invention relates to uses for such antibodies, such as therapeutic and pharmaceutical uses.
    Type: Application
    Filed: July 15, 2014
    Publication date: June 9, 2016
    Inventors: Soeren PADKJAER, Jesper PASS, Gustav ROEDER, Kasper ALMHOLT, Pemille A. USHER
  • Publication number: 20150274825
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: February 26, 2015
    Publication date: October 1, 2015
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Patent number: 9000127
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 7, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Publication number: 20140294853
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: May 1, 2014
    Publication date: October 2, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Patent number: 8765130
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: July 1, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Publication number: 20130336984
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: August 23, 2013
    Publication date: December 19, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Publication number: 20130330360
    Abstract: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: March 1, 2012
    Publication date: December 12, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Albrecht Gruhler, Susanne Nedergaard Grell, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Publication number: 20130309239
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: July 30, 2013
    Publication date: November 21, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer